Business Context and Reporting Period
Company: electroCore, Inc. (ECOR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A bioelectronic technology company focused on non-invasive devices for medical conditions (gammaCore, Quell) and general wellness (Truvaga, TAC-STIM). The company operates as a single segment: Bioelectronic Innovations. It is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Net Sales | $9,450 | $19,034 |
| Gross Profit | $8,177 | $16,541 |
| Gross Margin | 86.5% | 86.9% |
| Net Loss | $(3,059) | $(8,330) |
| Loss Per Share (Basic & Diluted) | $(0.33) | $(0.91) |
| Cash and Cash Equivalents | $8,501 | $8,501 (as of June 30) |
| Total Cash Position (incl. Marketable Securities) | $10,044 | $10,044 (as of June 30) |
| Total Debt (Current + Long-term) | $6,768 | $6,768 (as of June 30) |
| Stockholders' Deficit | $(2,790) | $(2,790) (as of June 30) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 28% ($2.1M) for the three months and 35% ($4.9M) for the six months ended June 30, 2026, compared to the prior year periods. Growth was driven by increased sales of Quell Fibromyalgia products (acquired May 2025) and prescription gammaCore devices to the U.S. Department of Veterans Affairs (VA).
- Operating Expenses: Total operating expenses increased by $1.0M (Q2) and $5.2M (YTD). Selling, general, and administrative (SG&A) expenses rose significantly due to variable selling expenses tied to revenue growth and one-time costs related to the former CEO's retirement ($1.2M severance) and legal fees.
- Interest Expense: Interest expense surged to $321,000 (Q2) and $639,000 (YTD) from negligible amounts in the prior year, primarily due to the new $7.5M term loan facility with Avenue Opportunities Fund II entered into in August 2025.
- Inventory: Inventory levels increased to $2.4M from $1.6M at year-end 2025, reflecting build-up for commercial activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The company has raised substantial doubt regarding its ability to continue as a going concern. Forecasted cash is insufficient to fund operating expenses and capital requirements for the next 12 months without additional financing.
- Liquidity Strategy: The company relies on equity and debt financings. It has an effective $100M Shelf Registration Statement and an At-The-Market (ATM) Sales Agreement with $15.7M remaining capacity. It raised approximately $3.9M via the ATM facility in Q2 2026.
- Customer Concentration: The U.S. Department of Veterans Affairs (VA) accounted for 75.8% of revenue in Q2 2026 and 75.3% for the six-month period. Sales are heavily dependent on the Federal Supply Schedule contract and the Lovell Government Services distribution agreement.
- Legal Proceedings: Ongoing patent litigation with UAB Pulsetto regarding non-invasive vagus nerve stimulation technology. The case is currently stayed for mediation until September 2026. The company has accrued $1.155M for litigation legal fees.
- Regulatory: The FDA issued a Form 483 letter in May 2026 regarding the NURO subsidiary (Quell product line) citing observations on patient complaint handling. The company has submitted a corrective action plan.
- Leadership Transition: The company is navigating a transition following the retirement of former CEO Daniel S. Goldberger in April 2026.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.0M cash position against the $6.5M operating cash burn rate for the first half of 2026 and upcoming debt principal repayments starting in 2027.
- VA Contract Renewal: Assess the risk associated with the 75% revenue concentration from the VA and the status of the Federal Supply Schedule contract expiring in 2030.
- Debt Covenants: Confirm continued compliance with the Avenue Loan and Security Agreement financial covenants (minimum revenue and cash levels) to avoid default.
- Equity Dilution: Monitor the pace of equity raises via the ATM facility and warrant exercises, noting the significant dilution potential given the current stock price and outstanding options/warrants.
- Litigation Outcome: Track the resolution of the Pulsetto patent dispute, as an adverse outcome could impact intellectual property rights and future revenue.